Radioligand Therapy Market Projected to Reach $15.85 Billion by 2035 as Alpha-Emitter Pipeline Matures
核心洞察
The radioligand therapy market was valued at USD 2.98 billion in 2025 and is forecast to reach USD 15.85 billion by 2035, an 18.2% CAGR.
Novartis received expanded FDA approval in 2026 for Pluvicto in earlier-line metastatic castration-resistant prostate cancer (搜索), moving PSMA (搜索) therapy ahead of chemotherapy.
Eli Lilly advanced 177Lu-PNT2002 into a pivotal Phase 3 trial in biochemically recurrent prostate cancer (搜索), while Convergent Therapeutics (搜索) began Phase III testing of CONV01-alpha (搜索).
The radioligand therapy market was valued at USD 2.98 billion in 2025 and is expected to reach USD 15.85 billion by 2035, growing at a compound annual growth rate of 18.2% from 2026 to 2035, according to market analysis that attributes the expansion to rising prostate cancer (搜索) and neuroendocrine tumor incidence, maturing PSMA (搜索)- and SSTR-targeting drug development, and the commercial success of Pluvicto and Lutathera.
The U.S. market alone was valued at USD 2.04 billion in 2025 and is projected to reach USD 10.68 billion by 2035, a CAGR of 18.00% over the same period, supported by existing theranostics infrastructure, an extensive tertiary academic cancer center network, and favorable Centers for Medicare & Medicaid Services reimbursement frameworks for FDA-approved radiopharmaceuticals.
Earlier-Line Approval Reshapes Prostate Cancer Treatment
In 2026, Novartis received expanded U.S. FDA approval for Pluvicto, now known as 177Lu-vipivotide tetraxetan (搜索), for an additional indication in earlier-line metastatic castration-resistant prostate cancer (搜索). The expanded label broadens the eligible patient population and establishes PSMA (搜索)-targeted radioligand therapy as a standard-of-care option ahead of chemotherapy, according to the source material.
Pluvicto held the largest product share of the radioligand therapy market in 2025 at 52.30% of revenues, supported by its status as the first and only FDA-approved PSMA (搜索)-directed radioligand therapy for metastatic castration-resistant prostate cancer (搜索), growing clinical familiarity, expanding insurance coverage, and demonstrated overall survival benefit versus standard-of-care therapies.
Novartis also broke ground in 2026 on a new radioligand therapy manufacturing facility in Indiana, expanding Lutetium-177 production capacity for Pluvicto and Lutathera.
Late-Stage Pipeline Momentum Across Beta and Alpha Emitters
Eli Lilly and Company advanced 177Lu-PNT2002, its PSMA (搜索)-targeted radioligand candidate obtained through the POINT Biopharma acquisition, into a pivotal Phase 3 trial for biochemically recurrent prostate cancer (搜索) in 2026, strengthening its U.S. late-stage radioligand pipeline.
In the alpha-emitter space, Convergent Therapeutics (搜索) advanced its actinium-225 labeled PSMA (搜索)-targeted radioligand CONV01-alpha (搜索) into a pivotal Phase III trial for metastatic castration-resistant prostate cancer (搜索) during 2026, described as one of the first late-stage registration trials for an actinium-225 based therapeutic. Fusion Pharmaceuticals (搜索), a subsidiary of AstraZeneca, reported positive interim data in 2026 for its actinium-225 labeled PSMA-targeted candidate FPI-2265 in patients with metastatic castration-resistant prostate cancer.
Bristol Myers Squibb (搜索) advanced RayzeBio (搜索)'s RYZ101 (225Ac-DOTATATE) through expanded enrollment in the pivotal ACTION-1 trial for somatostatin receptor (搜索)-positive gastroenteropancreatic neuroendocrine tumors (搜索) in 2026, while Novartis progressed a next-generation actinium-225 labeled PSMA (搜索) radioligand candidate into Phase II development, building on its Mariana Oncology radiopharmaceutical platform integration.
Bayer AG expanded U.S. manufacturing capacity in 2026 for Xofigo (radium-223 dichloride) to strengthen supply for bone-metastatic castration-resistant prostate cancer (搜索) patients.
Segment Dynamics: PSMA and Prostate Cancer Lead
By target receptor, PSMA (搜索) accounted for 61.20% of 2025 revenues, with the prostate-specific membrane antigen highly overexpressed on prostate cancer (搜索) cells compared with healthy cells, providing tumor-to-background ratios suited to both imaging and therapy. Emerging targets including gastrin-releasing peptide receptor (搜索) and fibroblast activation protein (搜索) represent the fastest-growing target segment at a 22.30% CAGR from 2026 to 2035, with preclinical and early clinical validation extending radioligand therapy beyond prostate cancer and neuroendocrine tumors (搜索) into solid tumors such as breast and pancreatic cancer.
By indication, prostate cancer (搜索) dominated with a 58.40% revenue share in 2025, while neuroendocrine tumors (搜索) are the fastest-growing indication segment at a 19.60% CAGR. The source material notes that many patients progress to metastatic castration-resistant disease unresponsive to androgen deprivation therapy and chemotherapy, and that trials in hormone-sensitive disease stages are expected to increase the eligible population. Pipeline candidates such as RayzeBio (搜索)'s 225Ac-DOTATATE and ITM Isotope Technologies' 177Lu-edotreotide are broadening options beyond currently approved therapies.
By end user, hospitals and specialized cancer centers held 64.10% of 2025 revenues, reflecting their role as clinical trial sites and their radiation safety and monitoring capabilities, while diagnostic and imaging centers are the fastest-growing segment at a 20.90% CAGR as PSMA (搜索) and SSTR PET imaging adoption expands for eligibility screening and post-therapy response monitoring.
Alpha Emitters Emerge as the Fastest-Growing Product Class
Pipeline products using Actinium-225 and Lead-212 as alpha-emitters represent the fastest-growing product segment, projected at a 24.60% CAGR from 2026 to 2035. Compared with beta emitters, alpha-emitters provide high linear energy transfer with shorter tissue penetration, creating an opportunity to demonstrate efficacy in patients refractory to beta-emitters.
The targeted alpha therapy market, tracked separately, was valued at USD 1,245.30 million in 2025 and is projected to reach USD 11,520.80 million by 2035, a CAGR of 24.9%. Radium-223 led by isotope type with a 39% share in 2025 on the strength of Bayer's Xofigo, the first-in-class alpha particle radiopharmaceutical approved for bone-metastatic castration-resistant prostate cancer (搜索) and the only one with an established commercialization and reimbursement pathway. Actinium-225 is the fastest-growing isotope segment, with developers including Convergent Therapeutics (搜索), Novartis, Fusion Pharmaceuticals (搜索), and Actinium Pharmaceuticals pursuing PSMA (搜索)-targeted and CD33 (搜索)-targeted candidates.
Within targeted alpha therapy, radioligand therapy held 61% of the market in 2025, while radioimmunotherapy is the fastest-growing therapy type, driven by alpha-emitting antibody constructs against CD33 (搜索), CD38 (搜索), and CD45 (搜索) for acute myeloid leukemia (搜索) and multiple myeloma (搜索). Prostate cancer (搜索) led by indication at 47% share, with leukemia and hematologic malignancies the fastest-growing indication.
In 2025, Orano Med (搜索) and Sanofi reported that AlphaMedix (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in its Phase 2 ALPHAMEDIX-02 study in gastroenteropancreatic neuroendocrine tumors (搜索).
Regional Infrastructure and Supply Constraints
North America held 80.50% of the radioligand therapy market in 2025, with the U.S. accounting for 85.60% of that regional share. In targeted alpha therapy, North America held 42.60% of global revenues, with the U.S. at approximately 85.90% of the regional total. Asia Pacific is the fastest-growing region in both markets, at a 21.50% CAGR for radioligand therapy and 28.30% for targeted alpha therapy from 2026 to 2035.
The source material identifies limited global production of radioactive isotopes such as Lutetium-177 and Actinium-225 — manufactured through specialized nuclear reactors or cyclotrons and available from only a few producers — as a principal restraint, alongside specialized infrastructure, radiation safety requirements, trained staff, and the short physical half-life of certain therapeutic isotopes that complicates logistics. High treatment costs and variable reimbursement frameworks, particularly in emerging economies, continue to constrain broader market penetration.
Expanding Lutetium-177 and Actinium-225 production capacity is easing historical radioisotope supply constraints across major manufacturing regions, and isotope manufacturers including NorthStar Medical Radioisotopes (搜索) and Eckert & Ziegler (搜索) are collaborating with clinical-stage biotech companies to address supply. Canada is investing in nuclear medicine infrastructure and domestic radioisotope production, particularly Molybdenum-99 and Lutetium-177, to reduce dependence on foreign suppliers.
Additional growth drivers cited include strategic acquisitions of clinical-stage radioligand developers by large pharmaceutical companies, expanding clinical exploration of radioligand combination regimens with immunotherapy, and growing use of PSMA (搜索) and SSTR PET diagnostics for patient selection.